NCT04496063进行中（未招募）4 期
USTekinumab in Fistulising Perianal Crohn's Disease (CD): The USTAP CD Study
Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives20 个研究点 分布在 1 个国家目标入组 33 人开始时间: 2020年11月16日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 33
- 试验地点
- 20
- 主要终点
- Combined clinical and radiological remission
研究概览
简要总结
Phase IV
Trial design : Multicentre, randomized, double-blind, placebo-controlled study
Population : Moderate to severe Crohn's disease with at least one active perianal fistula track
Investigational treatment : Group 1: Ustekinumab (UST) IntraVenous (IV) induction (6mg/kg) followed by UST SubCutaneous (SC) 90mg every 8 weeks. Group 2: Placebo IV followed by Placebo SC The trial duration for each patient will be 48 weeks.
Trial objective : To evaluate the efficacy and safety of ustekinumab in fistulizing perianal Crohn's disease.
Number of patients : A total of 146 patients will be included in 20 sites in France
Trial duration : First patient in: Q3 2020 - Last patient first visit: Q3 2022 Last patient last visit: Q3 2023
详细描述
Main endpoint:
The primary endpoint will be combined remission at week 12 defined as:
- 100% of the fistula tracts without any drainage by the external openings (occurring spontaneously or after gentle finger compression) And
- absence of collections >2 cm of the treated perianal fistulas confirmed by masked central MRI Patient requiring UST optimization will be considered in failure but will be followed until week 48
Secondary endpoints:
Definition
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥18 years
- •Adults with moderate to severe Crohn's disease for at least six months
- •Patients with at least one active perianal fistula track (between the anus or low rectum and the perineum or vulva) confirmed by MRI within the previous 12 weeks
- •Patients either naïve to anti-TNF therapy (50%) or refractory to anti-TNF therapy (50%).
- •If female, subject is either not of child bearing potential, defined as post-menopausal for at least1 year, surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy), or is of childbearing potential and practicing one of the following methods of birth control during the study and for 150 days after the last dose:
- •Condoms, sponge and foam, jellies with diaphragm or intrauterine device (IUD). IUDs may fail during azathioprine treatment. Alternative or additional contraceptive measures are advised, if azathioprine is initiated
- •Oral or parenteral contraceptives for 3 months prior to study drug administration
- •A vasectomized partner
- •Male subjects must agree to use an acceptable form of birth control, listed above at the start of azathioprine administration and for 90 days after last dose of azathioprine. Males should also commit to inform his partner(s) about it and to report any pregnancy to the investigator.
- •If female, subject is not breast-feeding throughout the study and for 150 days after last dose.
- •Subjects or his/her legal representative have voluntarily signed and dated an informed consent approved by and compliant with the requirements of this study protocol which has been approved by an Institutional Review Board (IRB)/Independent Ethics Committee (IEC)
- •Adequate cardiac, renal and hepatic function as determined by the Principal Investigator and demonstrated by Screening laboratory evaluations, questionnaires and physical examination results that do not indicate an abnormal clinical condition which would place the subject at undue risk and thus preclude subject participation in the study
- •Subject with a negative tuberculosis (TB) Screening Assessment [(including a Purified Protein Derivative (PPD) test < 5 mm and/or negative QuantiFERON-TB Gold test or equivalent and negative Chest X-Ray (CXR) (PA and lateral view)] at screening
排除标准
- •Absence of written consent. People unable to give their consent (because of their physical or mental state)
- •Pregnancy or breastfeeding
- •Rectovaginal fistulas
- •Rectal and/or anal stenosis
- •Diverting stomas
- •Abscess or collections >2 cm which are not properly drained ((i.e not drained at least 3 weeks before baseline and adequately treated provided that there is no anticipated need for any further surgery)
- •History of colectomy.
- •History of colonic mucosal dysplasia or adenomatous colonic polyps that are not removed.
- •Screening stool trial positive for enteric pathogens or Clostridium difficile toxin. History of ongoing, chronic or recurrent infectious disease
- •Positive HIV, Hepatitis B Virus (HBV),Hepatitis C Virus (HCV)
- •Severe infection, chronic infection, history of recurrent infections, active infection including TB
- •Malignancies or history of malignancies
- •History of congestive heart failure (NYHA: Grade III and IV), demyelinating disease, current signs or history of severe/ progressive/uncontrolled renal, hepatic, endocrine, pulmonary, cardiac, neurologic, cerebral, or psychiatric disease, or systemic lupus erythematosus (SLE).
- •History of transplanted organ, lymphoproliferative disease, any known malignancy
- •Previous allergy immunotherapy for anaphylaxis, hypersensitivity to ustekinumab or to any excipients, or metronidazole or ciprofloxacin
- •Previous use of a biologic agent targeting Interleukin 12 (IL12) and/or Interleukin 23 (IL 23), including but not limited to ustekinumab
- •Oral corticosteroids at a dose > 40 mg prednisone or its equivalent per day at inclusion (oral steroids should be at stable dose at least 7 days before inclusion)
- •Any current or previous use of the following within 8 weeks before the first trial agent injection : cyclosporine, tacrolimus, anti-TNF biologic agents or other agents intended to suppress or eliminate Tumor Necrosing Factor (TNF), and other biologics, including anti-integrin antibodies (approved or investigational), Janus Kinase (JAK) inhibitors (approved or investigational), or any current or previous use of an investigational agent
- •Non-autologous stem cell therapy or biologic agents that deplete B or T cells <12 months prior to baseline
- •Current or recent (less than 4 weeks) vaccination with attenuated live vaccines
- •Patients using a prohibited medication
- •Patients participating in another trial or being in a follow-up period for another trial
研究组 & 干预措施
Group 1 Ustekinumab
Experimental
Intravenous induction (6mg/kg) followed by Ustekinumab subcutaneous 90mg every 8 weeks
干预措施: Ustekinumab (Drug)
Group 2 Placebo
Placebo Comparator
Placebo intravenous followed by Placebo subcutaneous every 8 weeks
干预措施: Placebo (Drug)
结局指标
主要结局
Combined clinical and radiological remission
时间窗: Week 12
Number of participants with 100% of the fistula tracts without any drainage by the external openings (occurring spontaneously or after gentle finger compression) - Number of participants with absence of collections \>2 cm of the treated perianal fistulas confirmed by masked central MRI.
次要结局
- CDAI(week 12, week 24 and week 48)
- Combined clinical and radiological remission(week 24 and week 48)
- MAGNIFI-CD26(week 12, week 24 and week 48)
- IBDQ scores(week 24 and week 48)
- PDAI(week 12, week 24 and week 48)
- UST trough levels and antidrug(week 12 and week 24)
- Clinical response(week 12, week 24 and week 48)
- Clinical response of UST optimization(week 24 and week 48)
- Clinical response of UST introduction at week 12(week 24 and week 48)
研究者
研究点 (20)
Loading locations...
相似试验
招募中
不适用
Clinical Efficacy of Ustekinumab in Crohn's DiseaseCrohn's DiseaseNCT06523647Kazakhstan Scientific Society for Study of intestine diseases150
招募中
不适用
Efficacy of Ustekinumab Therapy in Patients With Symptomatic Stricturing Crohn's DiseaseCrohn DiseaseIntestinal StrictureBowel StrictureNCT05387031Second Affiliated Hospital, School of Medicine, Zhejiang University239
招募中
4 期
The USTAP CD trial
USTekinumab in fistulising Perianal Crohn’s Disease: The USTAP CD study2023-503380-42-00Groupe D'etude Therapeutique Des Affections Inflammatoires Du Tube Digestif146
Unknown
不适用
Real World Effectiveness of Ustekinumab in Induction and Maintenance Therapy for Crohn´s DiseaseCrohn DiseaseNCT03108326Ced Service GmbH900
已完成
2 期
A Study of Safety and Effectiveness of Ustekinumab in Patients With Moderate to Severe Active Crohn's Disease Who Have Been Previously Treated With Anti-TNF TherapyCrohn's DiseaseNCT00771667Centocor, Inc.526